Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Liarozole HCl is a benzimidazole derivative with antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits CYP450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, leading to an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. It also inhibits aromatase.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | Liarozole HCl is a benzimidazole derivative with antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits CYP450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, leading to an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. It also inhibits aromatase. |
Synonyms | R75251, Liarozole hydrochloride, R 75251, R-75251 |
Molecular Weight | 345.23 |
Formula | C17H14Cl2N4 |
CAS No. | 145858-50-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Liarozole HCl 145858-50-0 R75251 Liarozole hydrochloride R 75251 Liarozole Hydrochloride R-75251 inhibitor inhibit